Related references
Note: Only part of the references are listed.Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
Michael D. Shapiro et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience
Felice Gragnano et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2018)
Lipoprotein(a): A missing culprit in the management of athero-thrombosis?
Gianna Ferretti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies
Felice Gragnano et al.
ATHEROSCLEROSIS (2018)
High levels of lipoprotein (a) and premature acute coronary syndrome
Loukianos S. Rallidis et al.
ATHEROSCLEROSIS (2018)
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome Analysis of the dal-Outcomes Randomized Clinical Trial
Gregory G. Schwartz et al.
JAMA CARDIOLOGY (2018)
Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study
Federica Fogacci et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on
V. J. J. Schettler et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals
Haralampos J. Milionis et al.
ATHEROSCLEROSIS (2006)
Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients
R Marcucci et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2005)
Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty
L Chiarugi et al.
ATHEROSCLEROSIS (2001)
Share Paper
